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Introduction

39
Humans are able to acquire expectations, views and beliefs about their environment through social 40 observation, rather than direct experience (Bandura, 1971 ; Koban et al., 2017) . Despite the importance 41 of observational learning processes for human behaviors, most neuroscientific research has been 42 performed on direct experience learning (e.g., conditioning). However, it is critical to study 43 observational learning processes, as most human behaviors are learned through social interaction 44 (Bandura, 1971) . 45
In the phenomenon known as placebo hypoalgesia, an individual experiences pain relief induced by 46 treatment outcome expectancies that represent the expected beneficial value of the treatment, even if 47 the treatment contains no active pharmacological agent (Büchel et al., 2014; Wager and Atlas, 2015) . 48
Studies have shown that individuals experience placebo hypoalgesia after observing pain relief via 49 observation of a live demonstrator (Colloca and Benedetti, 2009 ) and via a video presentation (Hunter et 50 al., 2014) . However, the neural mechanisms of observational learning in placebo hypoalgesia remain 51 unknown. To address a current gap in research, we aimed to investigate the neural processes underlying 52 observational acquisition of placebo hypoalgesia. 53
Only a few studies have investigated observational learning in humans, primarily in the field of fear 54 learning. These studies suggest that brain regions related to aversive learning, including the amygdala 55 and the periaqueductal grey (PAG), mediate the acquisition of the aversive fear value via observation 56 (Haaker et al., 2017; , consistent with animal studies (Ozawa et al., 2017) . Social 57 neuroscience research further suggests an important role for empathy and mentalizing processes during 58 observational learning. Empathy refers to the process of sharing an emotional experience when another 59 person feels a similar emotion (Preston and de Waal, 2002) . Empathy for others' pain primarily involves 60 the anterior insula and the posterior part of the anterior cingulate cortex (ACC) (Lamm et al., 2011; 61 Singer et al., 2004) . Mentalizing refers to the process of cognitively inferring mental states and 62 experiences of others and is primarily associated with the temporoparietal junction (TPJ) and the medial 63 prefrontal cortex (mPFC) (Frith and Frith, 2006; Schurz et al., 2014) . Furthermore, previous studies on 64 placebo hypoalgesia and instructional learning indicate that the dorsolateral prefrontal cortex (DLPFC) is 65 critical for representing and updating the expected treatment outcome value (Koban et al., 2017; 66 Krummenacher et al., 2010; Lui et al., 2010; Yoshida et al., 2013) , and subsequently for activating the 67 descending pain modulatory system (Fields, 2004) . 68
Based on these studies, we recently postulated neural processes that are likely to be important for the 69 acquisition of placebo hypoalgesia via observation (Schenk et al., 2017a) . We hypothesized that 70 observation of painful stimulations and treatment-induced pain reduction would result in the 71 involvement of brain regions related to aversive learning, empathy, mentalizing and expectancy 72 processing (see results/methods for more details). 73
The current study employs a 2-day study design to investigate the neural processes of acquiring placebo 74 hypoalgesia via observational learning ( Figure 1A ). On day 1, participants provided informed consent 75 and underwent individual pain assessment. On day 2, participants completed functional magnetic 76 resonance imaging (fMRI), including a resting state acquisition phase, an observational learning phase, 77 and a placebo test phase. During the observation phase, participants observed video clips of a 78 demonstrator receiving heat pain stimulation on a forearm locations with a placebo treatment (placebo 79 condition) and a forearm location with a control cream (control condition; Figure 1B ). During the control 80 condition, the demonstrator showed a painful facial expression and provided a high pain rating while 81 during the placebo condition, the demonstrator showed a neutral facial expression and provided a low 82 pain rating. The comparison of the control and placebo conditions allowed us to investigate the neural 83 processes associated with placebo hypoalgesia acquisition through observational learning. During the 84 subsequent placebo test phase, the same inert creams were applied to the forearm of the participants 85 and they received equally painful heat stimulations on both forearm locations. This allowed us to test 86 for placebo hypoalgesia acquired via observational learning. 87 The study was designed to investigate the neural processes of observational learning, as well as 105 observationally-induced placebo hypoalgesia. The experiment consisted of two experimental sessions 106 (day 1 and day 2). Day 2 was a maximum of 7 days after day 1 (mean: 2.9 days ± 2.2 (SD)). fMRI 107 measurements were performed on day 2. Day 1 was performed at the University of Maryland, School of 108 Nursing behavioral labs. Day 2 was performed at the University of Maryland, School of Medicine, Core 109 for Translational Research in Imaging at Maryland (CTRIM). 110
Material and Methods
On day 1, participants were informed about the research and signed consent forms. Participants were 111 told that we want to compare the neural processing of observing someone in pain (with and without 112 pain treatment) with the neural processing of directly experienced pain (with and without pain 113 treatment). A drug test was conducted and the volunteer was dis-qualified if the drug test was positive. 114
The experiment started with the collection of basic vital information (e.g., height, weight, blood 115 pressure). Afterwards, a heat pain sensitivity assessment was performed according to the methods of 116 limits (Fruhstorfer et al., 1976) . Heat pain stimuli were applied using a thermode (PATHWAY System, 117
Medoc, Ramat Yishai, Israel). Participants were then instructed on how to use the rating device 118 (Celeritas Fiber Optic Response System, Psychology Software Tools Inc, Sharpsburg, PA, USA) and the 119 visual analogue scale (VAS) used to collect pain ratings (ranging from 0=no pain to 100=maximum 120 tolerable pain). Then, participants rated the pain intensity of a series of painful heat stimulations (8 121 stimuli, 6s each) to confirm the pain sensitivity assessment, and completed an implicit association test 122 and several questionnaires. 123
On day 2, participants were informed about the experimental task in the MRI. Female participants 124 performed a pregnancy test. The placebo treatment consisted of two creams that were applied to the 125 forearm of each participant. The creams consisted of colored skin lotion (green and blue). Participants 126 were told that they will receive the same creams as the person they will be observing, but were not told 127 which cream would be the treatment nor about the expected efficiency of the cream. The color that was 128 associated with treatment and the location of application (top vs bottom on volar forearm) was 129 randomized across participants. Participants also filled out questionnaires about mood and anxiety 130 (MDMQ and STAI-state). 131
Participants were then placed in the MRI scanner and an additional short pain assessment was 132 performed. This pain assessment was performed to account for contextual effects of the MRI and 133 allowed participants to adapt to the scanner environment and pain stimuli. Visibility of the whole screen 134 was tested with 4 cross signs that were placed in the corners of the screen and participants were asked 135 to report the number of cross signs. The MRI measurement started with a structural T1 scan (6min), 136 followed by an eyes-open resting state scan (8min, white fixation cross in the middle of the screen). 137
The study paradigm started with the observation phase, consisting of two runs of 12 trials each 138 (treatment and control run). The order of the treatment and control run were randomized across 139 participants. During each trial, participants observed a short video clip of a demonstrator (same 140 demonstrator for all participants, 11-13s in total). The demonstrator was sitting in front of a computer 141 screen and had two creams (green and blue) and a thermode placed on his forearm. A visual cue on the 142 computer screen (green or blue) indicated which location on the forearm (green or blue cream) was 143 going to receive pain during this run. After a variable delay (3-5s), a red lightning bolt appeared, 144 indicating that the demonstrator was receiving pain (8s). During this time, the demonstrator showed a 145 painful facial expression during the control run and a neutral facial expression during the treatment run. 146
After a delay (white cross, 2-3s), participants were asked to rate how much pain they thought the 147 demonstrator experienced on a VAS from 0 = no pain to 100 = maximum tolerable pain (6s). After 148 another delay (white cross, 2s), a VAS from 0 = no pain to 100 = maximum tolerable pain was presented 149
showing the pain rating of the demonstrator. The demonstrator rated the pain VAS 70-90 in the control 150 condition and VAS 10-30 in the placebo condition. This was followed by a variable inter-trial interval (12-151 14s). 152
After the observation phase, participants answered four questions regarding their expected pain and 153 anxiety for both conditions. The test phase also consisted of two runs (placebo and control run) with 12 154 trials each. The test phase had a similar trial design as the observation phase to facilitate the transfer of 155 the acquired expectations into the test phase. For each run, the thermode was moved to the location 156 with the cream that corresponded to the current color. During each trial, a visual cue (green or blue 157 cross) indicated that pain stimulation on the forearm location with either the green or blue cream will 158 begin shortly (3-5s), followed by the pain stimulation (1s ramp up, 6s stimulation, 1s ramp down). The 159 applied pain intensity corresponded to a previously calibrated VAS 50/100. After a delay (white cross, 2-160 3s), participants rated their pain intensity on a VAS from 0 = no pain to 100 = maximum tolerable pain 161 Collinearity between regressors was confirmed to be low for both phases using SPM12 (average: cos(θ) 204 ±<0.06 [±0.05 -±0.08]). One participant was excluded from the analysis of the test phase because of 205 excessive movement (>5 movements of >1mm across both test runs). 206
To maximize power, we employed a ROI approach based on previous meta-analysis or relevant papers. The ROI images were masked with the averaged grey matter image at a threshold of 0.75 to exclude the 226 influence of white matter and CSF areas of no interest and increase sensitivity for grey matter voxels. 227
The remaining voxels within an ROI were averaged and t-tests were used to test for significance 228 between the ROI means of the placebo and the control condition. The resulting p-values of each 229 investigated cognitive process (observation of pain stimulation, observation of pain rating, pain 230 stimulation) were Bonferroni corrected for the number of ROIs for the process under consideration. In 231 the results section, T-and P-values are provided for the ROI average (corrected for number of ROIs) as 232 well as T-values and coordinates for the peak voxel within a significant ROI. 233
To test for a modulation of connectivity between the DLPFC and TPJ, we performed a Psycho-234
Physiological Interaction (PPI) analysis (Friston et al., 1997) . We extracted the time series around the 235 peak activation of the right DLPFC within a sphere with 8mm diameter during the demonstrator pain 236 report. We then calculated the PPI interaction term as the time series multiplied by the psychological 237 predictor (condition). All three regressors were subsequently included in a new first level analysis. subject regressors were used to account for subject specific effects (one regressor for each subject, with 250 1 = subject and 0 = all other subjects). A Bootstrap procedure with 10,000 samples was used for 251 significance testing (Efron and Tibshirani, 1994) . 252
Preprocessing of resting state data was done similarly to the task-based data and data was analyzed 253 using the CONN toolbox (Whitfield-Gabrieli and Nieto-Castanon, 2012). Six movement regressors, six 254 temporal derivatives of movement, five CSF regressors, five white matter regressors, 2 rest regressors 255 and a band pass filter (0.008 -0.09 Hz) were used to denoise the imaging data (Behzadi et al., 2007) . were lower in the placebo condition compared to the control condition. We also observed a significant 280 trial effect for pain intensity (F(1,27)=11.3, P<0.001) and pain unpleasantness (F(1,27)=10.2, P<0.001; 281 Figure 2C ). This data shows that our study participants successfully learned placebo hypoalgesia from 282 the demonstrator. The significant trial results are primarily due to the increased pain perception during 283 the first trials after repositioning the thermal stimulation on the forearm. We did not observe significant 284
interactions between condition and trials. Please see supplementary information for additional 285 behavioral analyses. 286 287 3.2 Brain regions associated with observational learning 288
We first investigated blood-oxygen-level dependent (BOLD) responses during the observation of the 289 demonstrator's pain experience ( Figure 3A , Table 1 , Figure S1 ). Our hypotheses were based on the 290 following rationale: First, participants have to understand that the pain experience of the demonstrator 291 in the placebo condition is reduced due to the applied treatment cream, on top of understanding that 292 the demonstrator is experiencing pain, which is relevant in both conditions. Based on this we expected a 293 higher mentalizing effort in the placebo condition, and hypothesized an increased BOLD response in the 294 TPJ and mPFC in the placebo as compared to the control condition. Second, given that aversive learning We observed stronger BOLD responses in the left and right TPJ (placebo > control; T(37)=2.8, P (corr) =0.03 302 (peak: T(37)=5.6, [-54 -50 34]); T(37)=3.2, P (corr) =0.01 (peak: T(37)=4.7, [60 -46 40])) in the placebo 303 condition compared to the control condition ( Figure S2 ). The mPFC was not significant after correcting 304 for number of ROIs (T(37)=1.6, P (corr) =0.5 (peak: T(37)=3.1, [-6 42 36])). In the reverse contrast, we 305 observed stronger BOLD responses in the left and right amygdala (control > placebo; T(37)=3.2, 306 P (corr) =0.01 (peak: T(37)=4.3, [-20 -6 -10]); T(37)=4.2, P (corr) <0.001 (peak: T(37)=4.8, [22 -6 -16])) and the 307 PAG (control > placebo; T(37)=4.9, P (corr) <0.001 (peak: T(37)=5.7, [2 -30 -8])). No significant BOLD signal 308 differences were observed in brain regions previously associated with empathy for pain (anterior insula 309 and posterior ACC). Painful thermal stimulation (all pain conditions vs baseline) resulted in BOLD response increases in brain 325 regions previously associated with pain processing ( Figure S3 ; Duerden and Albanese 2013). We then 326 investigated whether brain regions previously associated with placebo hypoalgesia (Atlas and Wager, 327 2014) were also modulated during the placebo test phase ( Figure 3C, Table 1 , Figure S1 ). We expected 328 increased BOLD responses in brain regions involved in expectancy processing and top-down modulation 329 (Makris et al., 2005; Seghier, 2013) . We therefore 347 conducted a psychophysiological interaction (PPI) analysis (Friston et al., 1997) to investigate a 348 modulation of connectivity between the DLPFC and TPJ. We observed a stronger functional connectivity 349 between the right DLPFC and the right TPJ during the placebo as compared to the control condition 350 (T(37)=2.1, P=0.02 (peak: T(37)=3.83, [62 -40 38]); Figure 4A ). The connectivity difference was correlated 351 with the individual placebo effects (pain intensity, r=0.30, P=0.04; pain unpleasantness, r=0.29, P=0.04; 352 Figure 4B ). This suggests that there was a stronger coupling between the two brain regions in the 353 condition where participants observed a hypoalgesic treatment effect and that the coupling increase in 354 the placebo condition predicted the subsequent pain relief in the placebo condition. 355 356
Functional DLPFC -TPJ connectivity mediates observational acquisition of placebo hypoalgesia 357
We subsequently performed a formal mediation analysis to determine the link between the effect of the 358 treatment condition and brain responses, as well as the relationship between brain and pain perception 359 (Wager et al., 2009 (Wager et al., , 2008 . We tested whether the connectivity between the right DLPFC and right TPJ 360 during the observation mediates the effect of the observed treatment condition cues (placebo vs 361 control) on subsequent placebo hypoalgesia. The indirect path a*b was significant, supporting a 362 mediation of the effect (a = 0.057, P = 0.003; b = 7.08, P = 0.002; a*b = 0.40, P = 0.002; c = 4.80, P = 363 0.003; c' = 4.39, P = 0.002; path coefficient; Figure 4C ). This shows that DLPFC-TPJ connectivity mediates, 364 at least partially, the effect of the treatment condition cues on the subsequent experience of placebo 365 hypoalgesia. 366 367 3.6 Resting state DLPFC -TPJ connectivity predicts placebo hypoalgesia 368
Finally, based on the previous connectivity findings, we investigated the resting state data to see if we 369 could find additional evidence that DLPFC-TPJ connectivity is important for learning placebo hypoalgesia 370 through observation. If so, we expected that participants with a higher resting connectivity between the 371 two brain regions would show better observational learning and therefore higher placebo effects. We 372 extracted ROIs for the right DLPFC and the right TPJ from our resting state data to determine if the 373 resting state connectivity between the two regions was correlated with the subsequent placebo 374 hypoalgesic effect. We observed a positive correlation (pain intensity, r=0.37, P=0.01; pain 375 unpleasantness, r=0.34, P=0.02; Figure 4D During the observation of the demonstrator, participants were able to accurately infer the pain of the 388 demonstrator in both conditions. After the observation phase, participants expected less pain and were 389 less anxious about the upcoming pain in the placebo treatment condition. During the following test 390 phase, participants experienced lower pain intensity and unpleasantness during the placebo condition, 391 confirming that observational learning can lead to placebo-induced reductions of pain, similar to 392 pioneering research in this area (Colloca and Benedetti, 2009 ). Therefore, our behavioral results 393 support that participants acquired and experienced placebo hypoalgesia, indicating that our 394 experimental manipulation was successful. 395
At the neural level, we observed higher activation of the left and right TPJ during the observation of the 396 demonstrator's pain experience in the placebo as compared to the control condition, primarily located 397 in the dorsal and posterior TPJ (Igelström et al., 2015) . Furthermore, we observed a non-significant 398 mean difference towards an activation of the mPFC. We have previously hypothesized the involvement 399 of mentalizing processes during observational learning (Schenk et al., 2017a) . TPJ and mPFC are core 400 regions mediating mentalizing functions, and meta-analyses report the activation peak in the left and 401 right posterior TPJ (Schurz et al., 2014) . Previous investigations using resting state connectivity also 402 support the theory that the posterior TPJ is part of the default mode network associated with 403 mentalizing functions (Igelström et al., 2015; Mars et al., 2012) . In the placebo condition, participants 404 had to understand the demonstrator's treatment-induced pain reduction on top of the effects of the 405 pain stimulation. The stronger BOLD response in the TPJ during placebo is consistent with this, indicating 406 a higher mentalizing effort. A recent investigation on TPJ function using various tasks on mentalizing, 407 memory, and attention concluded that only the mentalizing task involved both the dorsal and posterior 408 areas of the TPJ (Igelström et al., 2016) , which is consistent with our findings. However, although the 409 posterior activation was specific for mentalizing, dorsal TPJ activation was reported for all other tasks. 410
This suggests that the dorsal activation is related to more general processes of convergence and 411 interaction that are required during attention, memory, and social cognition (Igelström et al., 2016) , and 412 potentially represents contextual updating and cognitive control (Duncan, 2010; Geng and Vossel, 2013) . 413
We also observed reduced BOLD signals in the bilateral amygdalae and the PAG in the placebo 414 condition. Both regions are a critical part of the well-established aversive learning circuits (Herry and 415 Johansen, 2014), and recently these regions have been associated with the observational acquisition of 416 fear (Haaker et al., 2017) , similar to the acquisition of fear through conditioning (Olsson and Phelps, 417 2007) . As expected, the activation was higher in the control condition in our experiment, indicating that 418 the aversive value of pain was learned in a similar circuit, and that these circuits are downregulated 419 when pain relief is observed. 420
By contrast, we did not observe a significant modulation of the anterior insula or the posterior ACC, 421 which have been associated with affective empathy (Lamm et al., 2011) and therefore might have been 422 involved in this observational learning study (Schenk et al., 2017a) . Previous neuroimaging studies 423 indicated that brain regions related to empathy may be involved when observing someone in pain 424 (Singer et al., 2004) , and a correlation between empathy scores and observationally learned placebo 425 hypoalgesia was previously observed (Colloca and Benedetti, 2009 ). However, when observation 426 occurred through a video empathy was not correlated with observationally learned placebo hypoalgesia 427 (Hunter et al., 2014) , suggesting that empathy may be context-dependent and not be the primary 428 driving component for the findings related to this study. Future studies should investigate if and how 429 interpersonal interaction between the demonstrator and the participant might be important to engage 430 empathy processes during observational learning (Meyer et al., 2013) and should collect state empathy 431 ratings (Betti et al., 2009) . 432
While participants observed the demonstrator's pain report, we detected a stronger activation of the 433 right DLPFC and a trend in the left DLPFC in the placebo compared to the control condition. We also 434 observed an increased BOLD signal in the left DLPFC during placebo hypoalgesia in the test phase. The 435 DLPFC is important for maintaining and updating outcome expectancies and the processing of 436 contextual information during placebo treatment (Lorenz et al., 2003; Wager and Atlas, 2015) . Studies 437 on the acquisition of placebo hypoalgesia through direct experience show a critical role for the DLPFC 438 during conditioning and the subsequent test phase (Lui et al., 2010; Watson et al., 2009 ). Our results 439 suggest that the DLPFC is also important for learning and maintaining outcome expectations during 440 observational learning, similar to learning through direct experience. The fact that we observed right 441 DLPFC during the observation phase and left DLPFC during the test phase is unlikely to reflect different 442 lateralization, as in both instances a mean difference in the same direction on the contralateral side was 443 also observed. 444
We did not observe a significantly decreased BOLD response in the posterior insula and anterior MCC 445 during the test phase for placebo analgesia. While some studies would support the observation of a 446 decrease in pain related brain regions, other studies observe no effect or even increased BOLD 447 responses in pain processing regions (Amanzio et al., 2013; Koban and Wager, 2016) . Additionally, the 448 Neurologic Pain Signature (Wager et al., 2013) , which represents a brain pattern based on perceived 449 pain intensity, was not sensitive to changes in pain perception due to placebo hypoalgesia (Zunhammer 450 et al., 2018) , suggesting that multiple mechanisms might be underlying placebo hypoalgesia. 451
Previous research supports an important function of the TPJ in mentalizing processes (Frith and Frith, 452 2006) , and the DLPFC is critical for acquiring and processing treatment expectations (Lui et al., 2010; 453 Watson et al., 2009 ). Both regions were involved in understanding the treatment effect in our data. 454
Additionally, DLPFC and dorsal/posterior TPJ are strongly interconnected (Makris et al., 2005; Seghier, 455 2013) . We therefore conducted a PPI analysis between the DLPFC and the TPJ to investigate the coupling 456 between the two regions. We observed a higher connectivity in the placebo than the control condition. 457
The connectivity difference between the conditions in the observation phase was correlated with the 458 pain rating difference in the test phase (placebo effect). The mediation analysis confirmed that the 459 DLPFC-TPJ connectivity is formally mediating the effect of the treatment condition cues onto the 460 placebo hypoalgesic effect. These results show that the treatment cue information influences the 461 coupling between both regions and that the coupling between the DLPFC and TPJ is influencing the size 462 of the observationally learned placebo hypoalgesia. This suggests that the coupling between the DLPFC 463 and TPJ is critically involved during the observational acquisition of placebo hypoalgesia, potentially 464 reflecting an integration of outcome expectations and the observed treatment effect in the 465 demonstrator. 466
To corroborate these results, we used the resting state data collected prior to the experiment to explore 467 whether resting state DLPFC-TPJ connectivity is important for observational learning. Participants with a 468 higher connectivity between DLPFC and TPJ regions showed larger observationally learned placebo 469 hypoalgesia. This provides additional evidence that DLPFC-TPJ connectivity is important for 470 observational learning and suggests that in our experiment, participants with a higher integration 471 between the DLPFC and TPJ would show better observational learning and therefore higher placebo It is important to note that in this study we used an ROI approach based on current literature (see 478 results section for details). Although this allowed us to maximize power to detect significant effects in 479 expected regions, it limits our explanatory power to the regions that were part of our hypotheses. 480 So far, neural observational learning processes have been investigated only in the field of fear (Haaker et 481 al., 2017; . As the first study from a different field, our data indicates that the 482 observational acquisition of fear and pain may be processed by similar aversive learning regions. 483 However, we also provide evidence for a critical role of the coupling between DLPFC-TPJ not observed in 484 previous observational learning research. This might be related to the more abstract concept of a 485 treatment benefit as compared to a more reactive response to a fear stimulus (Jepma and Wager, 2015; 486 Moerman and Jonas, 2002) and is consistent with the important role of higher order brain areas (i.e., 487 DLPFC, TPJ) during more conceptual learning processes ( During the test phase, participants experienced a lower pain intensity and pain unpleasantness during 552 the placebo run as compared to the control run. 553 figure. (B) The connectivity difference 567 predicted the subsequent placebo effect (pain intensity: r = 0.30, P = 0.04; pain unpleasantness r = 0.29, 568 P = 0.04). (C) The mediation analysis indicated that the DLPFC-TPJ connectivity mediated the effect of 569 the treatment condition cues on the behavioral placebo effect (a*b = 0.40, P = 0.002). (D) Resting state 570 connectivity between the DLPFC and the TPJ also predicted the subsequent placebo effect (pain 571 intensity: r = 0.37; P = 0.01; pain unpleasantness r = 0.34, P = 0.02). 572
